GSK announced a major breakthrough concerning cancer therapy. A drug called Jemperli (dostarlimab) showed impressive results in a phase 2 trial at the Memorial Sloan Kettering Cancer Center (MSK).

The safety and efficacy of dostarlimab plus chemotherapy in patients with advanced endometrial cancer were confirmed by ...

The drugmaker remains convinced of the potential of the drug, however, and has just reported results of a trial comparing Jemperli (dostarlimab) to Merck & Co's market-leading Keytruda ...

ANAB has a history of major successes under its belt. Among these, it discovered the anti pd-1 molecule, dostarlimab, which it licensed to GSK. Dostarlimab was approved as Jemperli for the ...

As we advance multiple trials evaluating belrestotug + dostarlimab in collaboration with GSK, we look forward to the topline interim results from GALAXIES Lung-201 in the second quarter of 2025 as ...

Dosing ongoing in Phase 1 clinical trial cohorts evaluating Claudin 18.2 ADC EO-3021 in combination with ramucirumab or dostarlimab in patients with advanced gastric/gastroesophageal junction (GEJ ...

Lurie Comprehensive Cancer Center (Lurie Cancer Center) of Northwestern University as a second site in a clinical trial combining the Company’s proprietary compound LB-100 with GSK’s Dostarlimab to ...